Ischemic Heart Disease Is Major Health Burden Worldwide
MONDAY, Oct. 19, 2020 -- A total of 126.5 million people lived with ischemic heart disease (IHD) globally in 2017, with 10.6 million new cases occurring, according to a study published online Oct. 5 in the European Heart Journal: Quality of Care & Clinical Outcomes.
Haijiang Dai, M.D., from York University in Toronto, and colleagues estimated the burden and risk factors for IHD in 195 countries and territories from 1990 to 2017 using data from the Global Burden of Disease Study.
The researchers found that 126.5 million people lived with IHD globally and 10.6 new cases of IHD occurred in 2017, resulting in 8.9 million deaths, 5.3 million years lived with disability, and 165 million years of life lost. Despite the decrease in age-standardized rates between 1990 and 2017, the global numbers of these burden metrics of IHD increased significantly. There was wide variation by geographic location in the burden of IHD in 2017 and its temporal trends from 1990 to 2017. In 2017, age-standardized IHD deaths worldwide were mainly attributable to dietary risks, high systolic blood pressure, high low-density lipoprotein cholesterol, high fasting plasma glucose, tobacco use, and high body mass index.
"As IHD is largely preventable and treatable, more strategies aimed at implementing cost-effective interventions and addressing modifiable risk factors are urgently needed, particularly in geographies with high or increasing burden," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: October 2020
Read this next
MONDAY, Nov. 23, 2020 -- Fresh takes on the efficacy of fish oil and vitamin D, new treatments for heart failure patients, the cardiovascular effects of COVID-19, and structural...
MONDAY, Nov. 23, 2020 -- Due to disproportionate representation, Black and Hispanic patients bear much of the burden of mortality and morbidity related to COVID-19, according to a...
MONDAY, Nov. 23, 2020 -- Many adolescent and young adult (AYA) survivors of acute myeloid leukemia (AML) experience late effects, with the most common being endocrine,...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.